ERBB2 and breast carcinoma: Clinically approved for HER2-positive breast cancer metastasis patients who have undergone one or more chemotherapy regimens, or in combination with paclitaxel for treating HER2-positive breast cancer metastasis patients without prior chemotherapy. (1998-09-25)